Aiforia Technologies Plc, Company release, May 18, 2026 17:00 EEST
Aiforia Technologies Plc: Disclosure under Chapter 9 Section 10 of the Securities Market Act - Mikko Laakkonen’s holding in Aiforia Technologies Plc
Mikko Laakkonen has informed Aiforia Technologies Plc that he has crossed above the 5% disclosure threshold on holding in shares and voting rights in Aiforia. According to the announcement, the holding passed above the threshold on May 8, 2026.
Total positions of Mikko Laakkonen subject to the notification:
| % shares and voting rights | % of shares and voting rights through financial instruments | Total of both in % | Total number of shares and voting rights of issuer | |
| Resulting situation on the date on which threshold was crossed or reached | 5.04% | 5.04% | 33,786,604 | |
| Positions of previous notification (if applicable) |
A: Shares and voting rights
| Number of shares and voting rights | % of shares and voting rights | |||
| Class/type of shares, ISIN code | Direct (AML 9:5) | Indirect (AML 9:6 and 9:7) | Direct (AML 9:5) | Indirect (AML 9:6 and 9:7) |
| FI4000507934 | 1,701,587 | 5.04% | ||
| SUBTOTAL | 1,701,587 | 5.04% | ||
Further inquiries
Antti Ojala, CFO, Aiforia Technologies Plc
tel. +358 40 7202448
https://investors.aiforia.com
Certified Adviser
UB Corporate Finance Ltd
ubcf@unitedbankers.fi
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.
Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.
Find out more at www.aiforia.com